Depo-Provera (medroxyprogesterone acetate) is a long-acting progestin contraceptive injection developed by Upjohn, a pharmaceutical company that later became part of Pfizer.
Originally formulated in the 1950s, medroxyprogesterone acetate was initially studied for potential use in treating endometrial and renal cancers due to its anti-proliferative effects on hormone-sensitive tissues.
However, researchers quickly recognized its ability to suppress ovulation and prevent pregnancy by inhibiting gonadotropin secretion, leading Upjohn to explore its use as a contraceptive.
Upjohn first sought U.S. Food and Drug Administration (FDA) approval for Depo-Provera as a contraceptive in the late 1960s, but the request was denied due to concerns about potential long-term health risks.
The primary reason for rejection was animal studies showing a link between medroxyprogesterone acetate and an increased risk of breast and endometrial cancers.
Despite these concerns, Depo-Provera gained approval in several international markets, including France in 1969 and later in developing countries, where it was widely promoted for population control efforts.
1992: U.S. Food and Drug Administration Approval
Upjohn continued pushing for U.S. approval throughout the 1970s, filing additional applications with the FDA in 1978 and 1983.
Each time, the FDA rejected the drug due to safety concerns, particularly over its potential carcinogenic effects and the risk of bone density loss.
However, in 1992—under mounting pressure from global health organizations and with additional safety studies in hand—the FDA finally approved Depo-Provera as an injectable contraceptive in the U.S.
The approval was controversial, as lingering concerns remained regarding its long-term safety profile, particularly for younger women who might use the drug for extended periods.
Medical Use and Long-Term Safety Concerns of Receiving Depo-Provera Injections
Depo-Provera became widely used due to its effectiveness and convenience, requiring only one injection every three months to prevent pregnancy.
By the early 2000s, millions of women worldwide were using Depo-Provera, with many health providers prescribing it as a first-line contraceptive option.
However, post-market surveillance studies and long-term clinical research began raising concerns about the drug’s safety.
In particular, studies linked Depo-Provera to significant bone mineral density loss, leading the FDA to issue a black box warning in 2004 cautioning against prolonged use beyond two years.
Further concerns emerged regarding its neurological and endocrine effects, particularly its influence on progesterone receptors in the brain.
While the drug was primarily marketed for contraception, it was also prescribed off-label for conditions such as endometriosis and menstrual suppression.
However, scientific research began drawing attention to the potential for high-dose progestins, like medroxyprogesterone acetate, to contribute to abnormal cell growth in hormone-sensitive tissues—including the meninges, the protective membranes surrounding the brain and spinal cord.
